The expanded service offering is available in both of the company's Lincoln and Zürich bioanalytical laboratories and includes ELISpot analysis, flow cytometry, and qPCR.
Celerion's expanded service offering provides platforms for immune monitoring and biomarker screening with high-throughput flow cytometry and ELISpot testing.
Celerion has a pre-qualified interferon gamma ELISpot assay, allowing for a significantly faster validation process with study-specific antigens, thereby accelerating the development process for cell and gene therapies and vaccines alike.
Celerion also supports vaccine development programs by offering fully automated ELISA assays in a Biosafety Level 2 environment.
Flow cytometry is used to support the drug development of cell, gene, and immunotherapies with endpoints including immune-phenotyping of immune cells and receptor occupancy assessment.
Celerion also provides high-throughput molecular biology testing for vector shedding analysis for gene therapies in compliance with current regulations as well as biodistribution to support GLP studies and transgene expression analysis using RT-PCR.
Farmen adds that Celerion has decades of regulatory experience, scientific excellence, and laboratory investments that enable accelerated development of these complex therapies.
Celerion is a specialist in early clinical research services.
Pfizer and BioNTech's Omicron XBB.1.5-adapted COVID-19 vaccine receives positive CHMP opinion in EU
Valneva's chikungunya vaccine moves forward with Health Canada's review
Allucent Awarded BARDA Contract to Support Acceleration of Next-Generation COVID-19 Booster Vaccines
Anixa Biosciences advances ovarian cancer CAR-T trial with third patient
GC Biopharma signs MoU with GC Biopharma for co-production of Euvichol
AusperBio receives FDA approval for AHB-137 trial in US
GC Biopharma partners with Eubiologics for joint cholera vaccine production
GSK's Shingrix shows 100% efficacy against shingles in Chinese adults